CD274 and non-small cell lung carcinoma: More recently in February 2021, data from the EMPOWER-Lung 1 clinical trial, documented a significantly improved OS and progression-free survival (PFS) with cemiplimab in patients with advanced NSCLC with PD-L1 of at least 50%, when compared with chemotherapy (Sezer et al., 2021).